This is the authors' abstract. We don't add key points for this paper.
Gestational Trophoblastic Neoplasia (GTN) involving the cervix is an uncommon and potentially life-threatening condition that poses significant diagnostic and therapeutic challenges. Early recognition and risk-adapted management are essential to achieve optimal outcomes. We report a 36-year-old woman with a prior history of molar pregnancy who presented with abnormal vaginal bleeding and systemic symptoms suggestive of malignancy. Laboratory evaluation revealed markedly elevated serum β-hCG levels, and imaging demonstrated a hypervascular cervical mass. The diagnosis of GTN involving the cervix was established based on clinical, radiologic, and biochemical findings. The patient was managed with EMA-CO chemotherapy (etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine) as per high-risk GTN protocol. She tolerated the regimen well with only mild adverse effects. Serial β-hCG monitoring demonstrated a consistent decline, and complete remission was achieved after 10 cycles of EMA-CO followed by 2 consolidation cycles. Follow-up imaging confirmed the absence of residual or recurrent disease. This case underscores the effectiveness of EMA-CO chemotherapy in achieving complete remission in high-risk GTN involving the cervix. It highlights the importance of early diagnosis, multidisciplinary coordination, and rigorous post-molar surveillance in improving outcomes for patients with this rare presentation.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Homenta et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: